VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Authors:
Open Access
- 6 November 2021
- journal article
- letter
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-7
Abstract
Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining PARP inhibition and VEGF-signalling, a cohort of patient-derived ovarian cancer xenografts (OC-PDXs), representative of the molecular characteristics and drug sensitivity of patient tumours, were treated with the PARPi olaparib and the VEGFR inhibitor cediranib at clinically relevant doses. The combination showed broad anti-tumour activity, reducing growth of all OC-PDXs, regardless of the homologous recombination repair (HRR) mutational status, with greater additive combination benefit in tumours poorly sensitive to platinum and olaparib. In orthotopic models, the combined treatment reduced tumour dissemination in the peritoneal cavity and prolonged survival. Enhanced combination benefit was independent of tumour cell expression of receptor tyrosine kinases targeted by cediranib, and not associated with change in expression of genes associated with DNA repair machinery. However, the combination of cediranib with olaparib was effective in reducing tumour vasculature in all the OC-PDXs. Collectively our data suggest that olaparib and cediranib act through complementary mechanisms affecting tumour cells and tumour microenvironment, respectively. This detailed analysis of the combined effect of VEGF-signalling and PARP inhibitors in OC-PDXs suggest that despite broad activity, there is no dominant common mechanistic inter-dependency driving therapeutic benefit.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG23520, IG19797, IG21320)
This publication has 13 references indexed in Scilit:
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerNew England Journal of Medicine, 2019
- Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativaScience Translational Medicine, 2019
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Science Translational Medicine, 2019
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerAnnals of Oncology, 2019
- Population exposure–safety analysis of cediranib for Phase I and II studies in patients with cancerBritish Journal of Clinical Pharmacology, 2017
- Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancerBritish Journal of Clinical Pharmacology, 2017
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerExpert Opinion on Investigational Drugs, 2016
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic AlterationsCancer Research, 2014
- Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine MechanismsThe American Journal of Pathology, 2014
- AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of CancerCancer Research, 2005